Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05582707 · ClinicalTrials.gov registry record · Phase 2
Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05582707: Clinical Trial Phase 2 study, sponsored by University of Maryland, Baltimore.
NCT05582707 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05582707, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH trial. This study will take approximately two years to complete.
Primary Outcome
Functional Improvement as determined by utility-weighted modified Rankin Scale (mRS) at 180 days. This is a scale from 0 to 6, where 0 is the best score (no symptoms) and 6 is the worst score.
Interventions
- DRUG Pioglitazone 15mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2025-12-25 |
| Phase | Phase 2 |
Why NCT05582707 stopped before completion
NCT05582707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Pioglitazone 15mg is the first listed.
NCT05582707 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05582707 about?
NCT05582707 is a clinical study titled "Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone". This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH...
What is the current status of trial NCT05582707?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-05-08. Estimated completion is 2025-12-25.
What interventions are being tested in trial NCT05582707?
The interventions under investigation include: Pioglitazone 15mg (DRUG).
Who is sponsoring clinical trial NCT05582707?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05582707's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI